PMID- 32626515
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 11
IP  - 16
DP  - 2020
TI  - mRNA Expression of FGFR1 as Potential Marker for Predicting Prognosis of Surgical 
      Resection of Small Cell Lung Cancer may be better than Protein Expression and 
      Gene Amplification.
PG  - 4691-4699
LID - 10.7150/jca.44476 [doi]
AB  - Purpose: Fibroblast growth factor receptor 1 (FGFR1) alterations have been 
      described in many cancers, including lung cancer, but the role has not been 
      elucidated specifically in small cell lung cancer (SCLC). The present study aimed 
      to identify the frequency of FGFR1 alterations among Chinese patients with 
      surgically resected SCLC and the association with the clinicopathological 
      characteristics and the survival were also investigated. Methods: FGFR1 protein 
      expression, FGFR1 amplification, FGFR1 mutations, and messenger RNA (mRNA) 
      levels, were determined by immunohistochemistry (IHC), fluorescence in situ 
      hybridization (FISH), polymerase chain reaction (PCR) and reverse 
      transcription-polymerase chain reaction (RT-PCR), respectively in primary tumors 
      from 33 patients with resected SCLC. Results: 7/33(21.2%) of the specimens were 
      positive for FGFR1 protein expression. FGFR1 amplification was identified in 4/28 
      cases (14.3%). If the cut-off value was determined to be 3.5, FGFR1 mRNA 
      positivity was considered in 7/33 cases (21.2%). However, no mutation was 
      detected in the 33 SCLC postoperative tissue specimens. No significant 
      association was observed between FGFR1 protein expression or amplification and 
      clinicalcharacteristics or prognosis. There was a distinct trend for mRNA level 
      and poor prognosis, including recurrence-free survival (RFS) (p = 0.07) and 
      overall survival (OS) (p= 0.08), but they did not reach statistical significance. 
      Conclusions: As novel FGFR1-targeted therapies are developed, FISH, IHC, 
      especially mRNA were detected, which should be considered as biomarkers of FGFR1 
      pathway dysregulation in SCLC.
CI  - (c) The author(s).
FAU - Qin, Jing
AU  - Qin J
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (lung and esophagus), Institute of Cancer Research and Basic Medical 
      Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
AD  - Department of Thoracic Medical Oncology, Institute of Cancer Research and Basic 
      Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of 
      Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
FAU - Xie, Fajun
AU  - Xie F
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (lung and esophagus), Institute of Cancer Research and Basic Medical 
      Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
AD  - Department of Thoracic Medical Oncology, Institute of Cancer Research and Basic 
      Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of 
      Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
FAU - Wang, Fenfang
AU  - Wang F
AD  - Graduate School, WenZhou Medical University, Wenzhou, 325035, P.R. China.
FAU - Lu, Hongyang
AU  - Lu H
AD  - Graduate School, WenZhou Medical University, Wenzhou, 325035, P.R. China.
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (lung and esophagus), Institute of Cancer Research and Basic Medical 
      Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
AD  - Department of Thoracic Medical Oncology, Institute of Cancer Research and Basic 
      Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of 
      Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC7330682
OTO - NOTNLM
OT  - FGFR1
OT  - amplification
OT  - mRNA expression
OT  - mutation
OT  - prognosis
OT  - protein expression
OT  - small cell lung cancer (SCLC)
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
PMCR- 2020/01/01
CRDT- 2020/07/07 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - jcav11p4691 [pii]
AID - 10.7150/jca.44476 [doi]
PST - epublish
SO  - J Cancer. 2020 May 22;11(16):4691-4699. doi: 10.7150/jca.44476. eCollection 2020.